GTS-21//DMXB-A CAS NO.156223-05-1

"In conclusion, GTS-21 was well tolerated up to doses of 450 mg/day (150 mg t.i.d.) and shows improvements in cognitive behavior in normal subjects. The pharmacokinetics appear to be linear over the range of dose

studies and the variability, primarily intersubject, decrease with con- tinued dosing. The data provide important evidence that GTS-21 has the potential to improve human cognitive function. The range of the

effects is important, clear benefits being seen to three major cognitive functions (attention, working memory, episodic secondary memory). In addi- tion, there appears to be a relationship between the duration and

magnitude of exposure to GTS-21 and/or 4-OH-GTS-21 and the magnitude of effect, with doses between 75 and 150 mg t.i.d. approaching maximal effect. GTS-21 may represent a novel treatment for dementia, and should

be investigated further for its potential therapeutic effects in a variety of conditions in which cognitive function is compromised, not least of all Alzheimer’s disease."